Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
15 Results for "
IDO/IDO/TDO_Inhibitor
" in MedChemExpress (MCE) Product Catalog:
Products (15)
15 Results for "IDO/IDO/TDO_Inhibitor" in MCE Product Catalog:
1
1 Cited Publications
Synonyms: IDO/TDO Inhibitor
Research Areas:
IACS-8968 (IDO/TDO Inhibitor) is a dual IDO and TDO inhibitor, with pIC50s of 6.43 for IDO and <5 for TDO, respectively.
Research Areas:
IDO/TDO-IN-1 (compound 25) is a highly potent and orally active dual indoleamine-2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) inhibitor with IC50s of 9.7 and 47 nM, respectively .
Synonyms: IDO/TDO Inhibitor (R-enantiomer)
Research Areas:
IACS-8968 (R-enantiomer) is the R-enantiomer of IACS-8968. IACS-8968 is a dual IDO and TDO inhibitor, with pIC50s of 6.43 for IDO and <5 for TDO, respectively.
Synonyms: IDO/TDO Inhibitor (S-enantiomer)
Research Areas:
IACS-8968 (S-enantiomer) is the S-enantiomer of IACS-8968. IACS-8968 is a dual IDO and TDO inhibitor, with pIC50s of 6.43 for IDO and <5 for TDO, respectively.
Cat. No.: HY-162962
Research Areas:
IDO1/TDO-IN-7 (Compound 43b), an isoquinoline derivative, is a potent dual IDO1/TDO inhibitor, with IC50s of 0.31 μM and 0.08 μM, respectively. IDO1/TDO-IN-7 displays acceptable pharmacokinetic profiles and potent antitumor efficacy with low toxicity in B16-F10 tumor model .
Cat. No.: HY-173513
CAS No.: 3085413-22-2
Research Areas:
IDO1/TDO-IN-8 (Compound CZ-17) is a dual IDO1 and TDO inhibitor that can penetrate the blood-brain barrier, with EC50 values of 0.33 μM and 1.78 μM, respectively. IDO1/TDO-IN-8 reduces the kynurenine/tryptophan ratio by regulating the kynurenine pathway of tryptophan metabolism. IDO1/TDO-IN-8 has a neuroprotective effect and can alleviate motor dysfunction and improve depressive behavior. IDO1/TDO-IN-8 can be used in the study of Parkinson's disease combined with depression .
Cat. No.: HY-184135
CAS No.: 1918946-83-4
Research Areas:
IDO1/TDO-IN-2 is an IDO1/TDO inhibitor with both human IDO1 and human TDO pIC50 ≥5.50. IDO1/TDO-IN-2 can be used for the research of cancer .
Cat. No.: HY-148336A
Research Areas:
IDO1/TDO-IN-5 (compound 9p-O) is a potent dual IDO1/TDO inhibitor with IC50 valeus of 18 and 25 nM, respectively .
Cat. No.: HY-184129
CAS No.: 2413970-98-4
Research Areas:
IDO1/TDO-IN-15 is a dual IDO1/TDO inhibitor with an IDO1 IC50 of 0.19 μM and a TDO IC50 of 0.37 μM. IDO1/TDO-IN-15 is applicable to the research of cancer and Alzheimer's disease .
Cat. No.: HY-184104
CAS No.: 537010-02-9
Research Areas:
IDO1/TDO-IN-17 is an IDO1/TDO inhibitor with human IDO1 IC50 ~280 μmol/L and human TDO IC50 204 μmol/L. IDO1/TDO-IN-17 binds to the heme-iron of IDO1. IDO1/TDO-IN-17 can be used for the research of cancer .
Cat. No.: HY-148336
CAS No.: 2407753-09-5
Target:
Research Areas:
(E)-IDO1/TDO-IN-5 is the E configuration of IDO1/TDO-IN-5 (HY-148336A). IDO1/TDO-IN-5 is a dual IDO1/TDO inhibitor with IC50 values of 0.018 and 0.025 μM, respectively .
Cat. No.: HY-184129A
CAS No.: 2414964-76-2
Research Areas:
(E)-IDO1/TDO-IN-15 is an isomer of IDO1/TDO-IN-15 (HY-184129). IDO1/TDO-IN-15 is a dual IDO1/TDO inhibitor with an IDO1 IC50 of 0.19 μM and a TDO IC50 of 0.37 μM. (E)-IDO1/TDO-IN-15 is applicable to the research of cancer and Alzheimer's disease .
Cat. No.: HY-184040
CAS No.: 2490673-04-4
Research Areas:
TDO-IN-3 (compound 20) is an IDO1/TDO inhibitor with IC50 values of 4.12 and 0.12 μM, respectively .
Cat. No.: HY-181941
Research Areas:
IDO1/TDO-IN-11 (Compound Y-13) is a dual IDO1 and TDO inhibitor, with an IC50 of 2.87 μM against hIDO1 and an IC50 of 0.08 μM against hTDO. IDO1/TDO-IN-11 inhibits NO production and ROS production. IDO1/TDO-IN-11 alleviates cellular neuroinflammatory damage and ameliorates Parkinson's disease. IDO1/TDO-IN-11 is applicable to research related to Parkinson's disease .
Cat. No.: HY-187530
Research Areas:
IDO1/TDO-IN-18 is a IDO1/TDO inhibitor with an IC50 of 26.54 μM against human IDO1 and an IC50 of 15.63 μM against human TDO. IDO1/TDO-IN-18 targets the apo-forms of IDO1 and TDO to displace the heme cofactor, attenuates the IDO1/SHP-2 interaction, reduces the output of the kynurenine pathway in tumor cells, and inhibits the proliferation and migration of cancer cells. IDO1/TDO-IN-18 can serve as a chemical probe for enzymology and signal transduction-related studies of the IDO1/TDO axis, and can also be used in cancer-related research .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
